Estrella Immunopharma, Inc. ESLA
Estrella Immunopharma, Inc. (Nasdaq: ESLA) is an oncology drug developer. Its lead program, EB103 (CD19-directed ARTEMIS T-cell therapy), is in Phase 2 for Relapsed/refractory B-cell non-Hodgkin lymphomas.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| EB103 | R/R B-cell non-Hodgkin lymphoma (STARLIGHT-1 Phase I/II) | cell therapy | Phase 2 |
| EB104 (CD19/CD22 dual-targeting ARTEMIS T cells) | B-cell malignancies | cell therapy | Pre-clinical |
| EB103 plus Imugene CF33-CD19t oncolytic virus (mark and kill) | Solid tumors | cell therapy | Pre-clinical |
Recent results and decisions
- Sep 1, 2026n/a Estrella Immunopharma receives Nasdaq deficiency notice for failing to maintain minimum $35 million market value of listed securities requirement, with compliance deadline of March 1, 2027.
The Company has been provided a compliance period of 180 calendar days, or until March 1, 2027, to regain compliance with the MVLS Requirement.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.